Vor Biopharma Inc. announced that new clinical data from Stage A of a Phase 3 study in China evaluating telitacicept in adults with IgA nephropathy (IgAN) will be presented as a late-breaking oral presentation at the American Society of Nephrology's Kidney Week 2025, scheduled for November 5-9, 2025, in Houston, Texas. The study, sponsored by RemeGen Co., Ltd, reported topline results in August, showing that telitacicept achieved the primary endpoint by reducing proteinuria, with a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared with placebo (p<0.0001). Telitacicept also demonstrated a favorable safety profile. Full results from Part A of the study will be presented at the conference. RemeGen has submitted a Biologics License Application to the National Medical Products Administration in China for this indication.